Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and approved under the brand name Mounjaro for type 2 diabetes and Zepbound for weight management. It represents the current gold standard in dual-agonist metabolic research, with Phase 3 clinical trial data showing up to 22% average body weight reduction — among the highest of any approved compound in its class.
Bangkok Peptide Center supplies Tirzepatide in 10mg lyophilised vials for laboratory research use. Each vial is third-party tested at 99%+ purity with Certificate of Analysis available on request.
About Tirzepatide
Tirzepatide works by simultaneously activating two incretin hormone receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual-receptor mechanism produces stronger metabolic effects than single GLP-1 agonists like semaglutide, making it one of the most studied compounds in metabolic disease research.
Unlike semaglutide which only targets GLP-1 receptors, tirzepatide’s additional GIP receptor activity is thought to enhance insulin secretion, improve insulin sensitivity, and produce greater reductions in appetite and body weight. The SURMOUNT Phase 3 clinical trial programme demonstrated average weight reductions of 20-22% over 72 weeks at the highest doses.
Tirzepatide vs Retatrutide
Researchers frequently compare tirzepatide and retatrutide as the two leading compounds in next-generation metabolic peptide research:
- Tirzepatide — dual GIP/GLP-1 agonist, FDA approved as Mounjaro/Zepbound, extensive Phase 3 data, ~20-22% weight reduction
- เรทแทรทรูไทด์ — triple GIP/GLP-1/Glucagon agonist, Phase 3 ongoing, ~24% weight reduction in Phase 2, not yet approved
The additional glucagon receptor activity in retatrutide is what differentiates the two — it increases energy expenditure directly, which may explain the higher weight reduction observed in Phase 2 trials. Bangkok Peptide Center supplies both — see our Retatrutide 10mg vials here.
Research applications
- Type 2 diabetes and insulin resistance models
- Obesity and body composition research
- Cardiovascular risk factor studies — SURPASS-CVOT data
- Non-alcoholic fatty liver disease (NAFLD) research
- Comparison studies with semaglutide and retatrutide
- Dual incretin receptor biology
Product specifications
Contents
10mg Tirzepatide lyophilised powder per vial
Purity
≥99% — third-party verified
Storage
Cool, dry place away from light. Refrigerate after reconstitution.
Included
Free bacteriostatic water and needles with every order
Delivery
Same-day delivery across Bangkok for orders placed before 12pm. Nationwide express available across Thailand. All orders dispatched in plain, unbranded packaging every day of the week. See our shipping page for full details.
For laboratory research purposes only. Tirzepatide supplied by Bangkok Peptide Center is not a medicine, not an approved pharmaceutical product, and is not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption.
รีวิว
ยังไม่มีบทวิจารณ์